Recombinant PDCD1 (Cemiplimab Biosimilar) 抗体
The 小鼠 单克隆 anti-PDCD1 (Cemiplimab Biosimilar) antibody is suitable to detect PDCD1 (Cemiplimab Biosimilar) in samples from 人. It has been validated for FACS 和 in vivo.
产品编号 ABIN7795092
发货至:
中国
Contact our Customer Service for availability and price in your country.
Contact Info
Our Local Distributor
中国
北京 101111
北京 101111
No. 88 KeChuang 6th Street
Beijing Economic Technological Development Area
Room 801-803
Quick Overview for Recombinant PDCD1 (Cemiplimab Biosimilar) 抗体 (ABIN7795092)
抗原
PDCD1 (Cemiplimab Biosimilar)
抗体类型
Recombinant Antibody
适用
人
宿主
小鼠
克隆类型
单克隆
标记
This PDCD1 (Cemiplimab Biosimilar) antibody is un-conjugated
应用范围
Flow Cytometry (FACS), In vivo Studies (in vivo)
质量等级
Research Grade
-
-
Expression System
- Mammalian cells
-
原理
- Cemiplimab Biosimilar, PD-1 Monoclonal Antibody
-
产品特性
- Cemiplimab Biosimilar uses the same protein sequences as the therapeutic antibody cemiplimab. PD-L1 and PD-L2 (B2-DC or CD273, programmed cell death ligand 2) are the two ligands for the receptor PD-1 (CD279, programmed cell death protein 1). Cemiplimab (anti-PD-1) is an intravenous human monoclonal antibody directed against programmed cell death-1 receptor (PD-1) and blocks its interaction with programmed death ligands 1 (PD-L1) and 2 (PD-L2). Cemiplimab blocks T-cell inactivation and enhances the immune system's anti-tumor response. Binding of the programmed death receptor (PD) ligands PD-L1 and PD-L2, to the PD-1 receptor inhibits T-cell proliferation and cytokine production. The upregulation of PD-1 ligands occurs in some tumors and signaling through this pathway may contribute to the inhibition of active T-cell immune surveillance of tumors. Cemiplimab is a recombinant human immunoglobulin G4 (IgG4) monoclonal antibody that binds to the PD-1 receptor and blocks its interaction with PD-L1 and PD-L2 ligands, causing PD-1 pathway-mediated inhibition of the immune response, including the anti-tumor immune response. In mouse tumor models, blocking PD-1 activity resulted in decreased rates of tumor growth.
-
纯化方法
- Protein A or G affinity column
-
纯度
- >95 % by reducing SDS-PAGE
-
内毒素水平
- < 1 EU per 1 mg of the protein by the LAL method
-
免疫原
- Human PD1
-
-
-
-
应用备注
- Optimal working dilution should be determined by the investigator.
-
限制
- 仅限研究用
-
-
-
状态
- Liquid
-
浓度
- > 3 mg/mL
-
储存条件
- 4 °C,-20 °C
-
储存方法
- Short time 2 to 8°C as supplied. Long time -20°C to -70°C as supplied.
-
-
- PDCD1 (Cemiplimab Biosimilar)
-
别名
- Cemiplimab Biosimilar
-
物质类
- Biosimilar
抗原
-
You are here:
